目的 采用显微CT技术评价复方中药方剂对慢性氟中毒大鼠氟骨症的治疗效果.方法 断乳2周的纯系Wistar大鼠88只,体质量(91.1±10.0)g,按体质量采用随机数字表法分为对照组、中氟组、高氟组、高氟低钙低蛋白组,分别为16、24、24、24只大鼠.中氟组、高氟组、高氟低钙低蛋白组染氟剂量分别为50、100、100 mg/kg,高氟低钙低蛋白组饲料中蛋白质与钙的含量为中氟组和高氟组的1/2.染氟6个月后,每组采用股动脉放血法处死8只大鼠;3个染氟组剩余16只大鼠又分为两小组,一组为持续染氟对照组,另一组模拟氟中毒病区实际情况在持续染氟的基础上用复方中药进行治疗,每天每只大鼠按100 g体质量给药194 mg,每周灌服6d;分别于治疗前和治疗后30、60d收集大鼠24h尿样.大鼠连续灌服90 d,股动脉放血法处死大鼠,分离四肢骨.氟离子选择电极法检测大鼠尿氟;高温灰化-氟离子选择电极法检测骨氟;显微CT技术检测大鼠四肢骨的骨矿物质密度(BMD)、组织骨密度(TMD)、结构模型指数(SMI)、骨小梁厚度(Tb.Th)、骨小梁分离度(Tb.Sp)、各向异性(a1/a3)、骨小梁连接密度(Conn.D)、骨小梁与全部骨组织体积比(BV/TV)、骨表面积与体积比(BS/BV)、骨小梁数目(Tb.N).结果 复方中药治疗后60d,高氟低钙低蛋白治疗组尿氟[(11.01±3.67)mg/L]低于高氟低钙低蛋白对照组[(34.32±9.50)mg/L,t=3.13,P＜ 0.05].复方中药治疗后90d,高氟治疗组骨氟[(275.38±171.65) mg/kg]低于高氟对照组[(701.67±178.16)mg/kg,t=5.42,P＜ 0.05],高氟低钙低蛋白治疗组骨氟[(313.26±124.51)mg/kg]低于高氟低钙低蛋白对照组[(794.66±261.35) mg/kg,t=3.25,P＜0.05].复方中药治疗后90d,各组大鼠Tb.Th、Tb.Sp、a1/a3、Conn.D、BV/TV、BS/BV、Tb.N组间比较差异有统计学意义(F值分别为2.785、2.681、3.039、27.231、2.595、2.854、5.050,P均＜0.05).其中中氟治疗组大鼠Tb.Th、Tb.Sp[(0.04±0.01)、(0.03±0.01)mm]高于中氟对照组[(0.02±0.00)、(0.02±0.00)mm,P均＜0.05],a1/a3、Conn.D、BV/TV、Tb.N[(0.77±0.61),(510.91±304.99)mm-3,(0.42±0.06),(13.58±2.48) mm-1]低于中氟对照组[(1.11±0.01),(2 403.69±124.02)mm-3,(0.46±0.03),(18.12±0.69)mm-1,P均＜0.05];高氟治疗组大鼠BV/TV(0.44±0.04)低于高氟对照组(0.49±0.00,P＜0.05),Tb.Th[(0.04±0.01)mm]高于高氟对照组[(0.03±0.00)mm,P＜ 0.05].结论 复方中药对大鼠氟骨症存在一定的治疗效果.
目的 採用顯微CT技術評價複方中藥方劑對慢性氟中毒大鼠氟骨癥的治療效果.方法 斷乳2週的純繫Wistar大鼠88隻,體質量(91.1±10.0)g,按體質量採用隨機數字錶法分為對照組、中氟組、高氟組、高氟低鈣低蛋白組,分彆為16、24、24、24隻大鼠.中氟組、高氟組、高氟低鈣低蛋白組染氟劑量分彆為50、100、100 mg/kg,高氟低鈣低蛋白組飼料中蛋白質與鈣的含量為中氟組和高氟組的1/2.染氟6箇月後,每組採用股動脈放血法處死8隻大鼠;3箇染氟組剩餘16隻大鼠又分為兩小組,一組為持續染氟對照組,另一組模擬氟中毒病區實際情況在持續染氟的基礎上用複方中藥進行治療,每天每隻大鼠按100 g體質量給藥194 mg,每週灌服6d;分彆于治療前和治療後30、60d收集大鼠24h尿樣.大鼠連續灌服90 d,股動脈放血法處死大鼠,分離四肢骨.氟離子選擇電極法檢測大鼠尿氟;高溫灰化-氟離子選擇電極法檢測骨氟;顯微CT技術檢測大鼠四肢骨的骨礦物質密度(BMD)、組織骨密度(TMD)、結構模型指數(SMI)、骨小樑厚度(Tb.Th)、骨小樑分離度(Tb.Sp)、各嚮異性(a1/a3)、骨小樑連接密度(Conn.D)、骨小樑與全部骨組織體積比(BV/TV)、骨錶麵積與體積比(BS/BV)、骨小樑數目(Tb.N).結果 複方中藥治療後60d,高氟低鈣低蛋白治療組尿氟[(11.01±3.67)mg/L]低于高氟低鈣低蛋白對照組[(34.32±9.50)mg/L,t=3.13,P＜ 0.05].複方中藥治療後90d,高氟治療組骨氟[(275.38±171.65) mg/kg]低于高氟對照組[(701.67±178.16)mg/kg,t=5.42,P＜ 0.05],高氟低鈣低蛋白治療組骨氟[(313.26±124.51)mg/kg]低于高氟低鈣低蛋白對照組[(794.66±261.35) mg/kg,t=3.25,P＜0.05].複方中藥治療後90d,各組大鼠Tb.Th、Tb.Sp、a1/a3、Conn.D、BV/TV、BS/BV、Tb.N組間比較差異有統計學意義(F值分彆為2.785、2.681、3.039、27.231、2.595、2.854、5.050,P均＜0.05).其中中氟治療組大鼠Tb.Th、Tb.Sp[(0.04±0.01)、(0.03±0.01)mm]高于中氟對照組[(0.02±0.00)、(0.02±0.00)mm,P均＜0.05],a1/a3、Conn.D、BV/TV、Tb.N[(0.77±0.61),(510.91±304.99)mm-3,(0.42±0.06),(13.58±2.48) mm-1]低于中氟對照組[(1.11±0.01),(2 403.69±124.02)mm-3,(0.46±0.03),(18.12±0.69)mm-1,P均＜0.05];高氟治療組大鼠BV/TV(0.44±0.04)低于高氟對照組(0.49±0.00,P＜0.05),Tb.Th[(0.04±0.01)mm]高于高氟對照組[(0.03±0.00)mm,P＜ 0.05].結論 複方中藥對大鼠氟骨癥存在一定的治療效果.
목적 채용현미CT기술평개복방중약방제대만성불중독대서불골증적치료효과.방법 단유2주적순계Wistar대서88지,체질량(91.1±10.0)g,안체질량채용수궤수자표법분위대조조、중불조、고불조、고불저개저단백조,분별위16、24、24、24지대서.중불조、고불조、고불저개저단백조염불제량분별위50、100、100 mg/kg,고불저개저단백조사료중단백질여개적함량위중불조화고불조적1/2.염불6개월후,매조채용고동맥방혈법처사8지대서;3개염불조잉여16지대서우분위량소조,일조위지속염불대조조,령일조모의불중독병구실제정황재지속염불적기출상용복방중약진행치료,매천매지대서안100 g체질량급약194 mg,매주관복6d;분별우치료전화치료후30、60d수집대서24h뇨양.대서련속관복90 d,고동맥방혈법처사대서,분리사지골.불리자선택전겁법검측대서뇨불;고온회화-불리자선택전겁법검측골불;현미CT기술검측대서사지골적골광물질밀도(BMD)、조직골밀도(TMD)、결구모형지수(SMI)、골소량후도(Tb.Th)、골소량분리도(Tb.Sp)、각향이성(a1/a3)、골소량련접밀도(Conn.D)、골소량여전부골조직체적비(BV/TV)、골표면적여체적비(BS/BV)、골소량수목(Tb.N).결과 복방중약치료후60d,고불저개저단백치료조뇨불[(11.01±3.67)mg/L]저우고불저개저단백대조조[(34.32±9.50)mg/L,t=3.13,P＜ 0.05].복방중약치료후90d,고불치료조골불[(275.38±171.65) mg/kg]저우고불대조조[(701.67±178.16)mg/kg,t=5.42,P＜ 0.05],고불저개저단백치료조골불[(313.26±124.51)mg/kg]저우고불저개저단백대조조[(794.66±261.35) mg/kg,t=3.25,P＜0.05].복방중약치료후90d,각조대서Tb.Th、Tb.Sp、a1/a3、Conn.D、BV/TV、BS/BV、Tb.N조간비교차이유통계학의의(F치분별위2.785、2.681、3.039、27.231、2.595、2.854、5.050,P균＜0.05).기중중불치료조대서Tb.Th、Tb.Sp[(0.04±0.01)、(0.03±0.01)mm]고우중불대조조[(0.02±0.00)、(0.02±0.00)mm,P균＜0.05],a1/a3、Conn.D、BV/TV、Tb.N[(0.77±0.61),(510.91±304.99)mm-3,(0.42±0.06),(13.58±2.48) mm-1]저우중불대조조[(1.11±0.01),(2 403.69±124.02)mm-3,(0.46±0.03),(18.12±0.69)mm-1,P균＜0.05];고불치료조대서BV/TV(0.44±0.04)저우고불대조조(0.49±0.00,P＜0.05),Tb.Th[(0.04±0.01)mm]고우고불대조조[(0.03±0.00)mm,P＜ 0.05].결론 복방중약대대서불골증존재일정적치료효과.
Objective To evaluate the treatment effect of compound Chinese medicine on skeletal fluorosis in rats by Micro-CT.Methods Eighty-eight Wistar rats which had been weaned for two weeks were divided into four groups according to body weight [(91.1 ± 10.0)g] by the method of random number table:control group(16 mts),middle fluorine(MF)group(24 rats),high fluorine(HF) group(24 rats),and high fluoride and low calcium low protein (HF-LC-LP) group (24 rats).The amounts of fluorine of MF,HF and HF-LC-LP groups were 50,100 and 100 mg/kg,respectively.The contents of calcium and protein in HF-LC-LP group were half of MF and HF groups.Six months after treatment with fluoride,eight rats of each group were put to death with femoral artery bleeding.The rest 16 rats of each fluorosis group were divided into two groups,one was the control group and the other was fed with both fluorine and the compound Chinese medicine which simulated the actual situation of fluorosis area.Each rat of the treatment group was given the medicine 194 mg/100 g for six days every week.Daily urine samples were collected when the medicine had been used for 0,30 and 60 days.All the rats were put to death with femoral artery bleeding after the medicine had beengiven for 90 days,and limbs bones were dissected.Urine fluoride was tested by the method of fluoride ion selective electrode ; bone fluoride was tested by the method of high temperature ashing-fluoride ion selective electrode; bone mineral density(BMD),tissue mineral density(TMD),structure model index (SMI),trabecular thickness (Tb.Th),trabecular separation (Tb.Sp),anisotropy (a1/a3),trabecular connection density(Conn.D),the volume ratio of trabecular and bone tissue,the ratio of bone surface area and volume(BS/BV),and trabecular number(Tb.N) were detected by Micro-CT technology.Results The level of urinary fluoride of high fluoride and low calcium low protein treatment group [(11.01 ± 3.67)mg/L] was lower than that of its control group [(34.32 ± 9.50)mg/L,t =3.13,P ＜ 0.05] when rats were remedied with the compound Chinese medicine for 60 days.The level of bone fluoride of high fluoride treatment group[(275.38 ± 171.65)mg/kg] was lower than that of its control group[(701.67 ± 178.16)mg/kg,t =5.42,P ＜ 0.05] when rats were remedied withy the compound Chinese medicine for 90 days; bone fluoride of high fluoride and low calcium low protein treatment group[(313.26 ± 124.51)mg/kg] was lower than that of its control group[(794.66 ± 261.35)mg/kg,t =3.25,P ＜ 0.05].The differences of Tb.Th,Tb.Sp,a1/a3,Conn.D,BV/TV,BS/BV and Tb.N among groups were statistically significant(F =2.785,2.681,3.039,27.231,2.595,2.854,5.050,all P ＜ 0.05).Tb.Th[(0.04 ±0.01)mm] and Tb.Sp[(0.03 ± 0.01)mm] of middle fluorine treatment group were higher than those of their control groups[(0.02 ± 0.00),(0.02 ± 0.00)mm,all P＜ 0.05]; al/a3,Corm.D,BV/TV and Tb.N[(0.77 ±0.61),(510.91 ± 304.99)mm-3,(0.42 ± 0.06) and (13.58 ± 2.48)mm-1] were lower than those of their control groups[(1.11 ± 0.01),(2 403.69 ± 124.02)mm-3,(0.46 ± 0.03) and (18.12 ± 0.69)mm-1,all P ＜ 0.05].BV/TV(0.44 ± 0.04) of high fluoride treatment group were lower than those of their control groups(0.49 ± 0.00,P ＜ 0.05) ; Tb.Th[(0.04 ± 0.01) mm] was higher than that of its control group [(0.03 ± 0.00)mm,P ＜ 0.05].Conclusion The compound Chinese medicine may has therapeutic effect on rat skeletal fluorosis.
